You are currently viewing The Abbott Vascular Bifurcation Program Transitioning Pathfinder to the Xience S.B.A. Platform

The Abbott Vascular Bifurcation Program Transitioning Pathfinder to the Xience S.B.A. Platform

The Abbott Vascular Bifurcation Program Transitioning Pathfinder to the Xience S.B.A. Platform

European Bifurcation Club 2011, EBC 2011 – Lisbon, Portugal

Abbott vascular sponsored Symposium

The Abbott Vascular Bifurcation Program Transitioning Pathfinder to the Xience S.B.A. Platform

AuthorDavid G. Rizik, MD, Scottsdale Heart Group at Scottsdale Healthcare Hospitals, USA

SUMMARY
  • There is no single, clear-cut regulatory pathway which ensures device approval.
  • SB devices (Capella, Tryton) require different randomized trial design and comparator arms than other devices (Xience SBA, Boston Scientific Petal etc…)
  • Where there is MB disease present, emphasis must remain on achieving durable main branch patency.
  • Greatest emphasis: SIMPLICITY, SIMPLICITY, SIMPLICITY!!!!!!
  • Devices need to be developed which can be applied broadly: i.e. to a heterogeneous pool of bifurcations including (and especially) LM disease.
  • Until recently, the psychology of treating bifurcation lesions has been focused on the provisional SB methodology as a “preferred” treatment strategy.However, with newer data now being published which confirms the merit of an upfront 2-stent strategy, it seems reasonable that those devices providing the greatest versatility are likely to enjoy the greatest adoption (i.e. a dedicated devices would be applicable to 1-stent and 2-stent strategies, Provisional SB stenting, and even a simple SB preservation technique)

Download here

Leave a Reply